Abstract
Purpose TNF inhibitors are established treatment for poly-juvenile idiopathic arthritis (pJIA), but there are needs of alternative therapy for refractory patients. Tocilizumab (TCZ) has been widely used for rheumatoid arthritis (RA) in adults, and the effectiveness for systemic JIA has been well-documented. However, the experience on pJIA is limited. We compared the clinical courses of our patients of RA and pJIA to estimate the effectiveness of TCZ.
Highlights
TNF inhibitors are established treatment for poly-juvenile idiopathic arthritis, but there are needs of alternative therapy for refractory patients
From 2011 Pediatric Rheumatology Symposium sponsored by the American College of Rheumatology Miami, FL, USA. 2-5 June 2011
We compared the clinical courses of our patients of rheumatoid arthritis (RA) and poly-juvenile idiopathic arthritis (pJIA) to estimate the effectiveness of TCZ
Summary
TNF inhibitors are established treatment for poly-juvenile idiopathic arthritis (pJIA), but there are needs of alternative therapy for refractory patients. Tocilizumab (TCZ) may be an effective treatment for poly-juvenile idiopathic arthritis (pJIA) as for rheumatoid arthritis (RA) From 2011 Pediatric Rheumatology Symposium sponsored by the American College of Rheumatology Miami, FL, USA. Purpose TNF inhibitors are established treatment for poly-juvenile idiopathic arthritis (pJIA), but there are needs of alternative therapy for refractory patients.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call